Clinical Trial Update: Dose-finding Study of MT-1303 in Subjects With Moderate to Severe Chronic Plaque Psoriasis [Phase 2]

View source ↗

Summary

This update reports completion of a Phase 2 dose-finding study of MT-1303 in adults with moderate to severe chronic plaque psoriasis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• MT-1303

Snippet

Sponsor: Tanabe Pharma Corporation | Conditions: Plaque Psoriasis | Phase 2 | Status: COMPLETED